Researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health (CVD) have completed a successful Phase 1 clinical trial of a novel vaccine designed to protect against both typhoid fever and…
Blog
-
Breaking dependency: Europe’s strategy for permanent magnets and critical materials
Supply chain disruptions are putting European car parts production and the green transition at risk. Recent export restrictions have exposed Europe’s dependence on external suppliers for permanent magnets and rare earth elements. These magnets are used throughout a vehicle: to start the engine, run the power steering, operate air conditioning and cooling systems, control braking, and support many other automated functions. CLEPA, the European association of automotive suppliers, has published a new position paper outlining urgent measures to secure industrial capacity, maintain competitiveness, and prevent future production stoppages.
“The supply chain challenges we face continue. With stockpiling virtually impossible, there is a continued risk of production stops in EU plants,” said CLEPA Secretary General Benjamin Krieger. “This is not just a temporary logistics issue – Europe’s full dependence on external suppliers poses a long-term structural risk that threatens EU competitiveness and undermines our ability to deliver on the green and digital transition.”
CLEPA’s position paper calls on the EU to adopt a cohesive and forward-looking strategy that addresses both direct and indirect dependencies across the critical raw materials value chain. Key recommendations include:
- Creating a competitive environment for raw materials projects
- Implementing short-term measures to prevent supply disruptions
- Developing a long-term European strategy for permanent magnets
- Fostering trade partnerships and strategic alliances
- Advancing coherent circularity strategies
- De-risking indirect dependencies
CLEPA emphasises the need for alignment with the EU’s broader industrial and environmental policies, including the Critical Raw Materials Act (CRMA) and the End-of-Life Vehicles Regulation (ELVR), to ensure Europe’s automotive industry remains resilient, competitive, and sustainable.
Continue Reading
-
Say It, Edit It – AI Edit Genie Rules Your Gallery with the realme 15 Series Party Revolution
Filters are officially outdated; it’s time to let AI take over your creativity! The upcoming realme 15 Series is setting a new standard in smartphone innovation with the introduction of its AI Edit Genie, a game-changing tool designed…
Continue Reading
-
Common medications may secretly rewire your gut for years
Medications a person took years ago can still influence the community of microbes living in their gut, according to a large study conducted by the University of Tartu Institute of Genomics.
By examining stool samples and prescription data from…
Continue Reading
-
New Global Standard for Hotel Excellence | Michelin – Groupe Michelin
- New Global Standard for Hotel Excellence | Michelin Groupe Michelin
- 7 hotels in Singapore make it to inaugural global Michelin Keys selection, Raffles Hotel Singapore earns 3 keys CNA Lifestyle
- Luxury Big Sur resort could win inaugural Michelin…
Continue Reading
-
Gender-Specific Next-Generation Sequencing Reveals First Allelic Varia
Introduction
Alzheimer’s disease (AD) represents the most common form of dementia, afflicting over 50 million people worldwide, with numbers projected to triple by 2050.1 Notably, epidemiological studies consistently demonstrate significant…
Continue Reading
-
SHIMANO launches a special edition in polished aluminum of its 10-speed CUES components
SHIMANO has presented a new and striking version of its CUES components. A special edition in polished aluminum that combines modern performance with the elegance of classic finishes. With this release, the Japanese firm…
Continue Reading
-
Official Announcement: Miguel Ángel Russo passes away – realmadrid.com
- Official Announcement: Miguel Ángel Russo passes away realmadrid.com
- Boca Jrs. coach Miguel Ángel Russo dies aged 69 ESPN
- Due to Russo’s passing, Boca vs Barracas match postponed OneFootball
- Argentina Russo Obit The Lufkin Daily News
- Boca…
Continue Reading
-
Kate warns too much screen time damages family life
The princess says that research evidence shows the importance of creating healthy and warm relationships within families and between people, with lifelong benefits for physical and mental health.
But she warns, in an essay The Power of Human…
Continue Reading
-
Resolution Therapeutics announces upcoming presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2025
– Dr Paul Brennan to present on the association of early biomarker modulation with long term clinical outcomes from the MATCH Ph II study of non-engineered macrophages in cirrhosis
– Dr Lara Campana to present on anti-inflammatory and anti-fibrotic effects of regenerative macrophage therapy in models of liver fibrosisEDINBURGH, Scotland and LONDON, Oct. 9, 2025 /PRNewswire/ — Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy in inflammatory and fibrotic diseases, today announces two abstracts have been selected for presentation at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2025. The conference will take place in Washington D.C., between 7-11 November 2025.
Dr Paul Brennan MD, PhD, Clinical Lecturer in Hepatology, University of Dundee, UK, will present data from the University of Edinburgh’s MATCH 2 clinical trial demonstrating that regenerative macrophage therapy (RMT) is associated with early changes in biomarkers associated with liver function (INR; dMELD), which in turn correlate with much longer survival in patients with advanced cirrhosis. Details below:
Title: Early modulation of INR and MELD after regenerative macrophage therapy is associated with favourable clinical outcomes at three-year follow-up
Publication Number: 2435
Author: Dr. Paul Brennan, PhD
Date/Time: 8 November 2025, 8:00am – 5:00pm EST
Track: Portal Hypertension and Other Complications of Cirrhosis (“2280-2479”)
Dr. Lara Campana, Ph.D., co-founder and Senior Vice President of Research and Translational Science at Resolution will present a poster detailing the preclinical data supporting the anti-inflammatory and anti-fibrotic effects of regenerative macrophage therapies in models of liver fibrosis. Details below:
Title: Assessment of regenerative macrophage therapy pharmacology supports anti-inflammatory and anti-fibrotic effects in preclinical models of liver fibrosis
Publication Number: 3391
Author: Dr Lara Campana, PhD
Date/Time: 9 November 2025, 5:00pm – 6:30pm EST
Track: Liver Fibrogenesis and Non-Parenchymal Cell Biology (“3335-3420”)
Members of the Resolution senior leadership team will be attending the conference. Please reach out to set up a meeting to learn more about the Company.
NOTES TO EDITORS
About Resolution Therapeutics
Resolution Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering regenerative macrophage therapy in inflammatory and fibrotic diseases. The Company leverages its proprietary platform to develop macrophages with pro-regenerative properties for superior patient outcomes. Resolution’s initial focus is on developing RTX001, its lead product with first-in-class potential supported by preclinical data demonstrating anti-fibrotic and anti-inflammatory advantages relative to non-engineered macrophages, to treat patients with end-stage liver disease. The Company is also advancing efforts to expand the potential of its platform into inflammatory and fibrotic indications beyond liver disease, including graft-vs-host disease (GVHD) and lung fibrosis. Resolution, a spinout from Professor Stuart Forbes’s lab at the University of Edinburgh, is based in Edinburgh and London. Learn more by visiting https://resolution-tx.com/ and engage with us on LinkedIn.
About AASLD
AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. It fosters research that leads to improved treatment options for millions of liver disease patients. It advances the science and practice of hepatology through educational conferences, training programs, professional publications, and partnerships with government agencies and sister societies.
SOURCE Resolution Therapeutics
Continue Reading